Articles tagged with Hormone Therapy
A study by Ann H. Partridge et al highlights the need for better patient-physician communication about fertility in young breast cancer patients. Fifty-seven percent of patients reported being very concerned about becoming infertile, with 29% influencing their treatment decisions.
Researchers found a 29% increased risk of all strokes and an 82% higher risk of ischemic stroke in women taking tamoxifen, compared to controls. The absolute increase in risk was small.
A study found that hormone therapy can limit heart muscle damage to 5% or cause permanent damage to 35%. Researchers are exploring how estrogen alone and other anti-inflammatory treatments may impact muscle damage. The study suggests different hormone therapies may have varying effects on postmenopausal women.
A recent study published in JAMA found that the use of estrogen plus progestin therapy was associated with an increased risk of venous thrombosis. The risk was higher among older and overweight postmenopausal women, as well as those with a genetic mutation for Factor V Leiden.
A Fox Chase Cancer Center study found IMRT to be cost-effective for men with intermediate-risk prostate cancer, improving quality-adjusted survival and reducing the need for additional treatments. The study's findings suggest that IMRT may offer better value compared to traditional conformal radiotherapy.
A clinical trial investigates botanicals like black cohosh and red clover for memory loss in menopause, exploring their potential as alternatives to hormone therapy. The study aims to understand how these therapies may influence brain function and cognitive performance.
A three-month study found that patients with type 2 diabetes preferred the prefilled NovoLog(R) Mix 70/30 FlexPen(R) disposable pen due to its ease of use and flexibility. Patients who had never used insulin before reported significant benefits in perceived clinical efficacy.
Researchers in The Netherlands and Belgium developed a new technique that uses genetically engineered rhTSH to stimulate thyroid cancer cells to absorb radioactive iodine, avoiding hypothyroidism and increasing safety. This approach may allow higher doses of radioiodine to be used when needed, improving treatment efficacy.
Researchers found that wastewater treatment plants employing reverse osmosis successfully removed more contaminants, including pharmaceuticals and hormones. This process improves the quality of reused water for irrigation and groundwater recharge.
Using combination therapies that include 6 months of androgen suppression therapy (AST) alongside radiation therapy (RT) improves survival rates for patients with locally advanced prostate cancer. The study found significantly higher survival rates, lower prostate cancer-specific mortality, and a reduced need for salvage AST in the com...
A randomized clinical trial found that combining six months of hormone therapy with radiation therapy reduced the risk of death from prostate cancer by two-fold. Patients treated with this combination therapy had a lower risk of requiring salvage hormone therapy in the long term.
Researchers found that short-term hormone therapy can be beneficial for women with mild to severe menopausal symptoms, but may not be suitable for those at high risk of cardiovascular disease. The study suggests that the decision to use hormone therapy should be based on individual goals and CVD risk.
Osteoporosis patients in US saw a four-fold rise in doctor visits from 1994 to 2003, driven by new medication availability. This trend shows improved treatment options for osteoporosis, but highlights the need for prevention strategies such as calcium use and physical activity.
A Cornell University-Stanford University meta-analysis of 30 clinical trials found that women starting HRT within two years of menopause had a lower total mortality risk. The study also showed significant reductions in hip fractures and recurrent urinary tract infections, but no change in breast cancer deaths.
Researchers found that using growth-hormone-releasing hormone (GHRH) therapy can increase normal growth hormone production and regulation in men with HIV lipodystrophy. This approach resulted in improved body composition, reduced fat deposits, and better cardiovascular health outcomes.
A new mouse model reveals that early pregnancy loss is triggered by the immune system's interference with reproductive hormones, specifically progesterone. This finding may contribute to human infertility and recurrent pregnancy loss, providing a potential target for therapy.
Researchers tested angiostatic therapy on mice with endometriosis lesions, finding it inhibited new blood vessel growth and reduced existing lesion size. The most effective compound was endostatin, which also showed no side effects in animal trials.
Researchers found that bicalutamide treatment resulted in increased bone mineral density, reduced body fat, and fewer side effects compared to leuprolide. This study suggests a single-drug treatment plan using bicalutamide may be an attractive alternative for men with non-metastatic prostate cancer.
Research suggests that estrogen therapy does not reduce the risk of dementia in older women. The study found a 76% increased risk for probable dementia among those taking estrogen compared to placebo. Hormone therapy also increased the risk of mild cognitive impairment and decline in global cognitive function.
A study found that estrogen alone did not reduce the risk of dementia in older women, doubling the risk compared to placebo. Global cognition also showed no improvement and was even adversely affected in some cases.
A recent study found that estrogen-alone hormone therapy may increase the risk of dementia in older postmenopausal women by 49%. This is compared to a placebo group where no such increase was observed. The researchers also found that almost half of the cases in both groups were Alzheimer's disease.
Researchers found a strong correlation between low DHEAS levels and reduced desire, arousal, and responsiveness in women under 45. The study suggests that low DHEAS may be a more accurate indicator of low libido than testosterone levels.
A new treatment using genetically engineered thyrotropin alfa eliminates the need to withhold thyroid hormone medication after thyroidectomy, reducing symptoms of hypothyroidism. The study shows that patients can be treated effectively without experiencing unpleasant side effects.
A new study suggests that early hormone therapy can increase survival time by up to 14 years for men with aggressive prostate cancer, compared to those who delay treatment. Prostate cancer affects over 220,000 men annually in the US, with approximately 30,000 dying from the disease each year.
Researchers found that estrogen combined with MPA caused increased aggression and anxiety, reduced sexual activity, and altered brain chemistry. The study provides insight into the behavioral effects of HRT and its potential links to depression, anxiety disorders, and premenstrual mood changes.
A global study led by Johns Hopkins Medicine found that docetaxel therapy significantly improves survival time for hormone-resistant prostate cancer patients. Patients treated with tri-weekly docetaxel survived 2.4 months longer than those receiving the standard chemotherapy drug, mitoxantrone.
A new study finds that estrogen therapy significantly improves verbal memory performance in men with advanced prostate cancer, while hormone deprivation impairs it. Estrogen also reduces depression and confusion in these patients.
A new study found that hormone deprivation therapy is less effective for younger men with higher grade tumors, suggesting it needs further investigation as an alternative treatment for localized prostate cancer. The study also revealed a higher risk of bone fractures in men on hormone therapy due to osteoporosis.
Researchers discovered a molecular marker, the HOXB13:IL17BR ratio, that accurately predicts the reoccurrence of tumors in breast cancer patients treated with tamoxifen. This finding suggests that HOXB13 may contribute to tumor invasion and metastasis.
Researchers found that tamoxifen-resistant breast cancers grow due to PKA-activated estrogen receptor modification. Identifying patients with activated PKA may lead to alternative treatments with aromatase inhibitors or fulvestrant.
New research indicates that hormone therapy may still offer important health benefits to postmenopausal women. The study's authors argue that the effects of different estrogens and progestins can vary significantly depending on formulation, dosage, and administration method.
Researchers at the University of Uppsala developed PQL, a diagnosis and treatment program that leads to improvement in stress management and overall well-being. The program uses psychosocial, biological, and production measures and has been shown to have a clear impact on sleep, concentration, and physiological factors.
Researchers found that estrogen therapy can suppress adrenal androgen production, with marked reductions in DHEA-S, A4, and testosterone levels. The study suggests a potential mechanism for how estrogen affects androgen hormones, and has implications for postmenopausal women.
The study found significant improvements in mood and sexual performance, with sustained increases in lean body mass and bone mineral density over 3.5 years. Researchers observed minimal skin irritation and no major adverse effects, paving the way for testosterone gel as a safe treatment option.
A study at Massachusetts General Hospital found that natural testosterone delivery products improved muscle strength and function in HIV-infected women with low testosterone levels. The treatment resulted in significant improvements in muscle mass and overall quality of life.
Drs. Thal and Nitsch receive the Potamkin Prize for their groundbreaking research on effective therapies to treat and prevent Alzheimer's disease. Their work has revitalized hopes for a vaccine and slowed cognitive decline in patients.
A randomized trial of conjugated equine estrogen found no significant effect on coronary heart disease risk, but increased stroke risk and reduced hip fracture risk. The study concluded that estrogen therapy has no overall benefit for chronic disease prevention in postmenopausal women with hysterectomy.
The estrogen-alone study, part of the WHI, found that women taking this form of hormone therapy had an increased risk of stroke, with 44 cases per 10,000 women per year. However, it did not reduce the risk of coronary heart disease. The study involved 10,739 postmenopausal women and was stopped early due to these findings.
A new study shows that preoperative anastrozole treatment can downstage tumors and allow more patients to undergo less extensive breast-conserving surgery, reducing the need for mastectomy. The treatment has been shown to be effective in improving outcomes for postmenopausal women with hormone receptor-positive breast cancer.
A study published in the New England Journal of Medicine found that women taking estrogen and progestin hormone replacement therapy had a lower risk of colorectal cancer, but those who developed cancer had more advanced cases. The researchers emphasize the importance of regular colonoscopy for women over 50.
Faslodex, a novel oestrogen receptor antagonist, has been approved by the EU for treating advanced oestrogen receptor-positive breast cancer. The drug offers durable responses and tolerability benefits compared to existing therapies, with a unique sustained release formulation administered monthly.
Researchers have found that urocortin II administered intravenously significantly enhances heart muscle cell contractions in mice with congestive heart failure. The hormone targets the CRF2 receptor, leading to improved cardiovascular function and a potential new treatment for heart disease.
A Phase II study investigates the effectiveness of black cohosh and red clover in alleviating hot flashes and other menopausal symptoms. The study aims to provide an evidence-based response for women seeking alternatives to hormone replacement therapy.
The National Institutes of Health has stopped the estrogen-alone study in healthy postmenopausal women due to an increased risk of stroke, but found no effect on heart disease. The trial also showed a decreased risk of hip fractures and no increase in breast cancer risk.
Researchers found that hormone replacement therapy (HRT) can lead to poorer hearing performance in women, especially in noisy environments. The study involved 32 women who had received HRT and compared their hearing with 32 women who had not.
A study found that bilateral mastectomy significantly lowers breast cancer risk in high-risk women with BRCA1 and BRCA2 mutations. Short-term hormone replacement therapy is safe after oophorectomy, increasing life expectancy by 3.34 to 4.65 years.
Postmenopausal hormone therapy has been associated with an increased risk of developing asthma in women, according to a study published in the Archives of Internal Medicine. Researchers found that current use of estrogen alone was linked to a 2.29 times higher risk of new asthma diagnoses compared to non-hormone users.
Type I diabetics experience bone loss due to insufficient amylin production, which reduces osteoclast cell activity. Amylin injection or pathway activation may help correct this issue and alleviate osteoporosis.
The American Association for the Advancement of Science recommends physicians consider risk factors and prevention options when prescribing hormone replacement therapy. Women with a high risk of chronic diseases may benefit from alternative treatments, while those with menopause-related symptoms may still be suitable candidates for HRT.
The study found that 82% of patients had polycystic ovary syndrome (PCOS), while 6.75% had specific identifiable underlying disorders. Combination hormonal therapy improved most symptoms, including hirsutism, acne, and menstrual dysfunction in 86%, 81%, and 80% of cases respectively.
The HABITS trial was terminated after an unacceptably high risk of recurrent breast cancer was found in women with previous breast cancer who received hormone therapy, compared to those without hormones. Women on active treatment have been advised to discontinue use.
A clinical trial was stopped early after showing an unacceptably high risk of breast cancer recurrence in women who received hormone therapy. The study found that even short-term use of HRT poses a significant risk, prompting the need for alternative safe and effective strategies for managing menopausal symptoms in these women.
A comprehensive review of 72 studies found no evidence that testosterone replacement therapy increases prostate cancer or cardiovascular disease risk. Testosterone therapy may alleviate symptoms of low testosterone levels, but monitoring is crucial due to potential side effects.
A study by NIH researchers found that low free testosterone levels may be associated with an increased risk of developing Alzheimer's disease in older men. The study, conducted on 574 men aged 32-87, revealed a 26% decrease in AD risk for every 50% increase in free testosterone index.
Physician response to hormone therapy and blood pressure medication changes is influenced by public awareness and media coverage. The studies found a significant drop in hormone therapy prescriptions following the announcement of risks associated with long-term use.
Recent evidence from randomized trials on hormone therapy and hypertension treatment led to a decline in hormone therapy prescriptions following publication of trial results. Alpha-blocker prescriptions also declined after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) early termination.
Researchers at OHSU discovered a novel compound called STX that activates a rapid signaling pathway in nerve cells, providing an alternative to estrogen replacement therapy. The new compound shows promise in alleviating menopause symptoms and may be more effective than existing treatments.
A novel model of human brain aging identifies midlife breakdown of myelin as a key factor in the onset of Alzheimer's disease later in life. Lifestyle changes, hormone replacement therapy, education, and treatment with common medications may help prevent myelin degradation.
A recent study found that over 20% of patients with estrogen-negative breast cancer had a complete pathologic response to treatment, compared to just 5% in estrogen-positive cancers. The researchers suggest that endocrine therapies may be a more effective initial treatment for these patients.
Researchers found that c-myc promotes androgen-independent growth in prostate cancer cells, slowing growth with downregulation. This suggests a physiological role for c-myc in prostate cancer and offers a possible therapeutic target.